Biotechnology Bulletin ›› 2019, Vol. 35 ›› Issue (8): 213-225.doi: 10.13560/j.cnki.biotech.bull.1985.2019-0099

Previous Articles     Next Articles

Current Status and Challenges of Epigenetic Drug Research and Development

JIANG Rui1, LÜ Ke-nao2, PAN Xue-feng1,2,3, CUI Xin-xia3, SHEN Shi-gang3, DING Liang1   

  1. 1. Department of Pharmacology,School of Medicine,Hebei University,Baoding 071000;
    2. Department of Life Sciences,School of life Science,Beijing Institute of Technology,Beijing 100081;
    3. School of Chemistry and Environmental Science,Hebei University,;Baoding 071000
  • Received:2018-03-12 Online:2019-08-26 Published:2019-08-05

Abstract: Epigenetic modifications do not affect DNA sequence,but do affect the expression of DNA genetic information by affecting the chromatin activity through DNA methylation/demethylation,reversible modifications of various histones,non-coding RNA molecules etc. Clinical drugs based on epigenetic mechanisms are intended to correct the expressions of the disease-associated genes by artificially interfering with the epigenetic modifications of the chromatins in the disease conditions,so as to achieve the preventions and treatments of diseases. To promote the research and development(R&D)of epigenetic drugs and its biotechnological industrialization in China,this paper systematically summarized the R&D current status of the epigenetic drugs,including DNA methyltransferase inhibitors,histone modifying enzyme inhibitors,siRNA,etc.,and also deeply discussed the critical issues that may need to be resolved in R&D and industrialization of epigenetic drugs.

Key words: epigenetic drug, DNA methylation inhibitor, histone modification inhibitor, siRNA